Core Viewpoint - Vili Medical (603309) reported its Q3 2025 financial results, showing significant growth in both revenue and net profit compared to the previous year [1] Financial Performance - Q3 2025 revenue reached 446 million yuan, representing a year-on-year increase of 16.09% [1] - Q3 2025 net profit was 70.566 million yuan, reflecting a year-on-year growth of 16.31% [1] - For the first three quarters of 2025, total revenue amounted to 1.191 billion yuan, with a year-on-year growth of 12.33% [1] - Net profit for the first three quarters of 2025 was 192 million yuan, showing a year-on-year increase of 14.94% [1] - Basic earnings per share for the period stood at 0.65 yuan [1]

格隆汇10月20日丨维力医疗(603309.SH)公布，前三季度实现营业收入11.91亿元，同比增长12.33%；归 属于上市公司股东的净利润1.92亿元，同比增长14.94%；归属于上市公司股东的扣除非经常性损益的净 利润1.84亿元，同比增长15.22%；基本每股收益0.65元。 ...

广州维力医疗器械股份有限公司 2025 年第三季度报告 证券代码：603309 证券简称：维力医疗 广州维力医疗器械股份有限公司 2025 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、主要财务数据 （一） 主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | 年同期增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 446,011,096.01 | 16.09 | 1,191,172,720.75 | ...

第一条 为规范广州维力医疗器械股份有限公司（以下简称"公司"）董事、 高级管理人员离职相关事宜，确保公司治理的稳定和连续，维护公司及股东的合 法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）等法律法规、 规范性文件及《广州维力医疗器械股份有限公司章程》（以下简称"《公司章程》"） 的有关规定，结合公司实际情况，制定本工作制度。 第二条 本制度适用于公司董事（含独立董事）及高级管理人员因任期届满、 辞职、被解除职务或其他原因离职的情形。 第二章 离职情形与程序 第三条 公司董事和高级管理人员离职包括任期届满未连任、主动辞职、被 解除职务、退休及其他导致董事和高级管理人员实际离职的情形。 公司董事和高级管理人员可以在任期届满前辞职，董事和高级管理人员辞职 应当提交书面辞职报告，辞职报告中应说明辞职原因。董事辞职的，自公司收到 辞职报告之日辞职生效；高级管理人员辞职的，自董事会收到辞职报告时生效。 董事、高级管理人员辞职的，公司应依据法律法规、《公司章程》的相关规定及 时履行信息披露义务。 第四条 如存在下列情形，在改选出的董事就任前，原董事仍应当依照法律、 行政法规、部门规章和《公司章程》的规定，继 ...

证券代码：603309 证券简称：维力医疗 公告编号：2025-061 投资者可于 2025 年 10 月 24 日（星期五）至 10 月 30 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 visitor@welllead.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 广州维力医疗器械股份有限公司（以下简称"公司"）已于 2025 年 10 月 21 日发布公司 2025 年第三季度报告，为便于广大投资者更全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划于 2025 年 10 月 31 日（星期五） 10:00-11:30 举行 2025 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以视频录播结合网络文字互动召开，公司将针对 2025 年 第三季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信 息披露允许的范围内就投资者普遍关注的问题进行回答。 广州维力医疗器械股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存 ...

证券代码：603309 证券简称：维力医疗 公告编号：2025-060 广州维力医疗器械股份有限公司 第五届董事会第十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 广州维力医疗器械股份有限公司（以下简称"公司"）第五届董事会第十七 次会议的会议通知和材料于2025年10月11日以电子邮件方式发出，会议于2025 年10月20日上午10点在公司会议室以现场结合通讯的方式召开，会议由董事长向 彬先生主持。会议应出席董事7名，亲自出席董事7名。其中，独立董事芦春斌先 生、独立董事臧传宝先生因出差在外，以通讯表决方式参与本次会议。公司全体 高级管理人员列席了会议。本次会议的召集和召开程序符合《公司法》等有关法 律、行政法规、部门规章、规范性文件和《公司章程》的相关规定，会议形成的 决议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，以记名书面投票表决方式一致通过以下决议： 1 级管理人员离职管理制度》。（全文同日刊登在上海证券交易所网站 （http://www.sse.com.cn ...

Group 1 - The company reported a revenue of 1.191 billion yuan for the first three quarters, representing a year-on-year growth of 12.33% [1] - The net profit attributable to shareholders of the listed company reached 192 million yuan, with a year-on-year increase of 14.94% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 184 million yuan, reflecting a year-on-year growth of 15.22% [1] - The basic earnings per share stood at 0.65 yuan [1]

Core Viewpoint - The company reported a significant increase in revenue and net profit for the third quarter of 2025, indicating strong financial performance and growth potential in the healthcare sector [1] Financial Performance - In Q3 2025, the company achieved a revenue of 446 million yuan, representing a year-on-year growth of 16.09% [1] - The net profit attributable to shareholders for Q3 2025 was 70.57 million yuan, reflecting a year-on-year increase of 16.31% [1] - For the first three quarters of 2025, the company recorded a total revenue of 1.191 billion yuan, which is a year-on-year growth of 12.33% [1] - The net profit attributable to shareholders for the first three quarters was 192 million yuan, showing a year-on-year increase of 14.94% [1]

Core Viewpoint - The company, Weili Medical, is set to repurchase and cancel 996,600 restricted stocks due to unmet performance targets, resulting in a reduction of its total share capital by October 22, 2025 [2][3]. Trading Information Summary - On October 17, 2025, Weili Medical's stock closed at 13.21 yuan, down 1.49%, with a turnover rate of 1.0%, trading volume of 29,100 shares, and a transaction value of 38.6875 million yuan [1]. - On the same day, the net outflow of main funds was 1.907 million yuan, accounting for 4.93% of the total transaction value, while retail investors saw a net inflow of 3.2 million yuan, representing 8.27% of the total transaction value [1][3]. Company Announcement Summary - Weili Medical's decision to repurchase and cancel 996,600 restricted stocks affects 77 incentive recipients, with 990,000 stocks being fully canceled due to unmet performance criteria for the third release period, and 6,600 stocks canceled from the second release period [2]. - The repurchase price for the first grant is adjusted to 5.55 yuan per share, while the reserved grant is set at 5.27 yuan per share, funded by the company's own resources [1][2]. - The company has completed all necessary decision-making procedures, and the legal opinion confirms compliance with laws and regulations regarding the repurchase and cancellation [2].

Core Points - Vili Medical's stock price decreased by 2.58% to 13.21 yuan as of October 17, 2025, with a total market capitalization of 3.869 billion yuan [1] - The company ranks 95th out of 126 in the medical device sector and 3875th out of 5158 in the A-share market [1] Company Announcements - Shareholder Guangzhou Songwei Enterprise Management Consulting Co., Ltd. holds 39,064,856 shares, accounting for 13.34% of the total share capital [1] - On October 9, 2025, Guangzhou Songwei pledged 14,600,000 shares, representing 37.37% of its holdings and 4.99% of the total share capital, for debt investment [1] - On October 10, 2025, Guangzhou Songwei released a previous pledge of 19,350,000 shares, which accounted for 49.53% of its holdings and 6.61% of the total share capital [1] - The company will repurchase and cancel 996,600 restricted shares due to unmet performance targets, reducing the total share capital from 292,868,018 shares to 291,871,418 shares [2][3] - The repurchase price for the initial grant is set at 5.55 yuan per share, while the reserved grant is at 5.27 yuan per share, funded by the company's own resources [2]